NervGen Pharma Corp. (NASDAQ:NGEN) experienced a stock increase of 5.29% during premarket trading on Tuesday, following the announcement of positive results from its Phase 1b/2a CONNECT SCI study. The Vancouver-based biopharmaceutical company reported that its lead candidate, NVG-291, demonstrated a statistically significant improvement in gait quality for patients with chronic spinal cord injuries, as evidenced by an independent analysis conducted by Newton Tech. Notably, all ten treated subjects were classified as responders, compared to just one in the placebo group, highlighting the potential efficacy of NVG-291. NervGen's CEO, Adam Rogers, emphasized that these results bolster the company's plans to progress into a Phase 3 RESTORE study, anticipated to commence in mid-2026. Despite the positive momentum, NGEN stock remains significantly below its short-term moving averages, with key resistance at $3.65 and support at $1.98, indicating critical levels for investors to monitor as the stock navigates its recovery.